Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients

Katherine C. Fuh, Angeles A. Secord, Kerri S. Bevis, Warner Huh, Adam Elnaggar, Kevin Blansit, Rebecca Previs, Todd Tillmanns, Daniel S. Kapp, John K. Chan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). Methods A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed. Results Of 277 patients (median age: 58 years), the majority had Stage III and IV (86%) disease, and 72% had serous histology. 244 (88%) were treated with C + Bev and 33 (12%) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7 months, and median overall survival (OS) was 14.3 and 10.5 months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n = 19, OS of 20.4 months), taxanes (n = 55, OS of 20.2 months), gemcitabine (n = 106, OS of 14.1 months), topotecan (n = 43, OS of 13 months), and cyclophosphamide (n = 21, OS of 13 months). There was no significant difference in toxicities between the C + Bev vs. Bev alone group. Conclusion This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.

Original languageEnglish (US)
Pages (from-to)413-418
Number of pages6
JournalGynecologic oncology
Volume139
Issue number3
DOIs
StatePublished - Dec 1 2015

Fingerprint

Ovarian Neoplasms
Drug Therapy
Survival
Disease-Free Survival
gemcitabine
Topotecan
Bevacizumab
Taxoids
Combination Drug Therapy
Cyclophosphamide
Histology
Demography

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Fuh, K. C., Secord, A. A., Bevis, K. S., Huh, W., Elnaggar, A., Blansit, K., ... Chan, J. K. (2015). Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecologic oncology, 139(3), 413-418. https://doi.org/10.1016/j.ygyno.2015.06.041

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. / Fuh, Katherine C.; Secord, Angeles A.; Bevis, Kerri S.; Huh, Warner; Elnaggar, Adam; Blansit, Kevin; Previs, Rebecca; Tillmanns, Todd; Kapp, Daniel S.; Chan, John K.

In: Gynecologic oncology, Vol. 139, No. 3, 01.12.2015, p. 413-418.

Research output: Contribution to journalArticle

Fuh, KC, Secord, AA, Bevis, KS, Huh, W, Elnaggar, A, Blansit, K, Previs, R, Tillmanns, T, Kapp, DS & Chan, JK 2015, 'Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients', Gynecologic oncology, vol. 139, no. 3, pp. 413-418. https://doi.org/10.1016/j.ygyno.2015.06.041
Fuh, Katherine C. ; Secord, Angeles A. ; Bevis, Kerri S. ; Huh, Warner ; Elnaggar, Adam ; Blansit, Kevin ; Previs, Rebecca ; Tillmanns, Todd ; Kapp, Daniel S. ; Chan, John K. / Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. In: Gynecologic oncology. 2015 ; Vol. 139, No. 3. pp. 413-418.
@article{2b4f1f7a810f4a51ac5c5266ed48abfd,
title = "Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients",
abstract = "Background To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). Methods A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed. Results Of 277 patients (median age: 58 years), the majority had Stage III and IV (86{\%}) disease, and 72{\%} had serous histology. 244 (88{\%}) were treated with C + Bev and 33 (12{\%}) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7 months, and median overall survival (OS) was 14.3 and 10.5 months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n = 19, OS of 20.4 months), taxanes (n = 55, OS of 20.2 months), gemcitabine (n = 106, OS of 14.1 months), topotecan (n = 43, OS of 13 months), and cyclophosphamide (n = 21, OS of 13 months). There was no significant difference in toxicities between the C + Bev vs. Bev alone group. Conclusion This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.",
author = "Fuh, {Katherine C.} and Secord, {Angeles A.} and Bevis, {Kerri S.} and Warner Huh and Adam Elnaggar and Kevin Blansit and Rebecca Previs and Todd Tillmanns and Kapp, {Daniel S.} and Chan, {John K.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.ygyno.2015.06.041",
language = "English (US)",
volume = "139",
pages = "413--418",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients

AU - Fuh, Katherine C.

AU - Secord, Angeles A.

AU - Bevis, Kerri S.

AU - Huh, Warner

AU - Elnaggar, Adam

AU - Blansit, Kevin

AU - Previs, Rebecca

AU - Tillmanns, Todd

AU - Kapp, Daniel S.

AU - Chan, John K.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). Methods A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed. Results Of 277 patients (median age: 58 years), the majority had Stage III and IV (86%) disease, and 72% had serous histology. 244 (88%) were treated with C + Bev and 33 (12%) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7 months, and median overall survival (OS) was 14.3 and 10.5 months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n = 19, OS of 20.4 months), taxanes (n = 55, OS of 20.2 months), gemcitabine (n = 106, OS of 14.1 months), topotecan (n = 43, OS of 13 months), and cyclophosphamide (n = 21, OS of 13 months). There was no significant difference in toxicities between the C + Bev vs. Bev alone group. Conclusion This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.

AB - Background To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). Methods A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed. Results Of 277 patients (median age: 58 years), the majority had Stage III and IV (86%) disease, and 72% had serous histology. 244 (88%) were treated with C + Bev and 33 (12%) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7 months, and median overall survival (OS) was 14.3 and 10.5 months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n = 19, OS of 20.4 months), taxanes (n = 55, OS of 20.2 months), gemcitabine (n = 106, OS of 14.1 months), topotecan (n = 43, OS of 13 months), and cyclophosphamide (n = 21, OS of 13 months). There was no significant difference in toxicities between the C + Bev vs. Bev alone group. Conclusion This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.

UR - http://www.scopus.com/inward/record.url?scp=84949674322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949674322&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2015.06.041

DO - 10.1016/j.ygyno.2015.06.041

M3 - Article

VL - 139

SP - 413

EP - 418

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -